Showing results (101-110 of 119) with videos related to
Sort By:
Pageof 12
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2014
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trialS Leyvraz, S Piperno-Neumann, S Suciu, et al.Leukemia|August 5, 2005
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia GroupsS Amadori, S Suciu, R Stasi, et al.Leukemia|May 17, 2003
The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)M Oosterveld, S Suciu, G Verhoef, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon GroupB Löwenberg, S Suciu, E Archimbaud, et al.Blood|October 6, 2001
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDST de Witte, S Suciu, G Verhoef, et al.Leukemia|August 26, 2006
Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trialU Jehn, S Suciu, X Thomas, et al.Bone Marrow Transplantation|June 1, 1996
Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative GroupsS Keating, S Suciu, T de Witte, et al.Bone Marrow Transplantation|November 18, 2014
High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMTM Hengeveld, S Suciu, Y Chelgoum, et al.Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|May 26, 2021
CNS-3 status remains an independent adverse prognosis factor in children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: Results of EORTC Children Leukemia Group study 58951N Sirvent, S Suciu, B De Moerloose, et al.Leukemia|September 24, 2010
NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951E Clappier, S Collette, N Grardel, et al.Pageof 12